TrialJournal of Alzheimer's disease : JAD2019

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of PF-06751979, a Potent and Selective Oral BACE1 Inhibitor: Results from Phase I Studies in Healthy Adults and Healthy Older Subjects.

Ruolun Qiu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.